.jpg "Analysts Are Bullish on These Healthcare Stocks: PBYI, TEVA")
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Puma Biotechnology (NYSEArca: PBYI) and Teva Pharma (NYSE: TEVA) with bullish sentiments.
Puma Biotechnology (NYSEArca: PBYI)
Credit Suisse analyst Alethia Young maintained a Buy rating on Puma Biotechnology (NYSEArca: PBYI) yesterday and set a price target of $106. The company’s shares closed yesterday at $64.55.
According to TipRanks.com, Young is a 2-star analyst with an average return of 0.5% and a 43.2% success rate. Young covers the Healthcare sector, focusing on stocks such as Alexion Pharmaceuticals, Sarepta Therapeutics, and Coherus Biosciences.
Puma Biotechnology has an analyst consensus of Moderate Buy, with a price target consensus of $97.40.
See today’s analyst top recommended stocks >>
Teva Pharma (NYSE: TEVA)
In a report issued on May 6, Vamil Divan from Credit Suisse maintained a Buy rating on Teva Pharma (NYSE: TEVA), with a price target of $23. The company’s shares closed yesterday at $18.62.
According to TipRanks.com, Divan is ranked 0 out of 5 stars with an average return of -3.1% and a 40.9% success rate. Divan covers the Healthcare sector, focusing on stocks such as Aimmune Therapeutics, Johnson & Johnson, and Portola Pharma.
Currently, the analyst consensus on Teva Pharma is Hold and the average price target is $18.04, representing a -3.1% downside.
In a report released yesterday, Mizuho Securities also reiterated a Buy rating on the stock with a $27 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on TEVA:
